Predictors of 12-Month Outcome in Smokers Who Received Bupropion Sustained-Release for Smoking Cessation

[31] Kanner R(1991)The Fager-strom test for nicotine dependence: a revision of the Fager-strom Tolerance Questionnaire Br J Addict 86 1119-27

[32] Bailey W(2003)Measures of abstinence in clinical trials: issues and recommendations [published erratum appears in Nicotine Tob Res 2003; 5: 603] Nicotine Tob Res 5 13-25

[33] Gonzales DH(2003)Bupropion SR and counseling for smoking cessation in actual practice: predictors of outcome Nictone Tab Res 5 911-21

[34] Nides MA(2000)A nationwide, multi-center, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia Diag Microbiol Infect Dis 36 145-58

[35] Ferry LH(1998)Risk classification after aneurysmal subarachnoid hemorrhage Surg Neurol 49 155-63

[36] Jack LM(2001)Bone marrow features improve prognostic efficiency in multivariate risk classification of chronic-phase Ph(1) chronic myelogenous leukemia: a multicenter trial J Clin Oncol 19 2994-3009

[37] Swan GE(2005)Repeated split sample validation to assess logistic regression and recursive partitioning: an application to the prediction of cognitive impairment Statist Med 24 3019-35

[38] Thompson E(2001)Cigarette smoking among adults: United States, 1999 MMWR Morb Mortal Wkly Rep 50 869-73

[39] Swan GE(1996)Cost-effectivess of the transdermal nicotine patch as an adjunct to physicians’ smoking cessation counseling JAMA 275 1247-51

[40] McAfee T(1999)Prescription of transdermal nicotine patches for smoking cessation in general practice: evaluation of cost-effectiveness Lancet 354 210-5

[31] Kanner R(1991)The Fager-strom test for nicotine dependence: a revision of the Fager-strom Tolerance Questionnaire Br J Addict 86 1119-27

[32] Bailey W(2003)Measures of abstinence in clinical trials: issues and recommendations [published erratum appears in Nicotine Tob Res 2003; 5: 603] Nicotine Tob Res 5 13-25

[33] Gonzales DH(2003)Bupropion SR and counseling for smoking cessation in actual practice: predictors of outcome Nictone Tab Res 5 911-21

[34] Nides MA(2000)A nationwide, multi-center, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia Diag Microbiol Infect Dis 36 145-58

[35] Ferry LH(1998)Risk classification after aneurysmal subarachnoid hemorrhage Surg Neurol 49 155-63

[36] Jack LM(2001)Bone marrow features improve prognostic efficiency in multivariate risk classification of chronic-phase Ph(1) chronic myelogenous leukemia: a multicenter trial J Clin Oncol 19 2994-3009

[37] Swan GE(2005)Repeated split sample validation to assess logistic regression and recursive partitioning: an application to the prediction of cognitive impairment Statist Med 24 3019-35

[38] Thompson E(2001)Cigarette smoking among adults: United States, 1999 MMWR Morb Mortal Wkly Rep 50 869-73

[39] Swan GE(1996)Cost-effectivess of the transdermal nicotine patch as an adjunct to physicians’ smoking cessation counseling JAMA 275 1247-51

[40] McAfee T(1999)Prescription of transdermal nicotine patches for smoking cessation in general practice: evaluation of cost-effectiveness Lancet 354 210-5